Page 9 - Diabetes

Zydus gets regulator nod to market generic diabetes drug in American

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Pharma company Abbott ties up with health tech firms for diabetes care

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care

India's diabetes care market to reach $60 bn in next 10 yrs: Report

The diabetes care market in India is expected to reach about $60 billion in the next 10 years, from approximately $17 billion in FY2021, a new report said

Statsguru: Obesity to diabetes, 6 charts explain health concerns for India

Data shows that obesity is increasingly growing among both men and women

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

IMA urges Covid vax, including booster dose if needed, for all diabetics

Noticing their vulnerabilities, IMA on Sunday demanded Covid-19 vaccination for all diabetes patients, including a third dose, if needed. The IMA on Sunday launched a campaign for early detection and mitigation of diabetes complications with organising of walkathon, marathon, screening camps, and a social media drive. The campaign also included research paper promotion among young doctors and an "intense" personal intervention at hospitals. The campaign, launched on the occasion of world Diabetes Day, will run for 10 days and will aim to reach one billion people, the Indian Medical Association (IMA) said in a statement. As part of the campaign, the IMA has joined hands with the association of Physicians of India, RSSDI, Endocrine Society, and many other niche organisations. As per the data from the 10th Edition of the IDF Diabetes Atlas, diabetes caused 6.7 million deaths in 2021, with 537 million adults (aged 20 to 79 years) around the world currently living with the condition.

Post-Covid fatigue is most prevalent in diabetes patients: Study

People with Type-2 diabetes who also suffered Covid-19 are more likely to experience severe fatigue than those who did not have the infectious disease, according to a new study released on Thursday

Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

NPPA fixes price caps for 12 anti-diabetic medicines

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet

Study finds why people with diabetes develop severe Covid-19

A recent study by a team of international clinical researchers reveals the mechanism behind cytokine storm during coronavirus infection.

Startup Sugar.fit, which aims to reverse diabetes, to raise $10 million

Health and fitness firm Cure.fit and two others to invest the funds in a deal likely to by September

Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy

In India, Wockhardt aims to make 2 billion doses of Covid-19 vaccines within the next one or two years but has not disclosed the identity of the tie-ups

Ethnic diversity helps identify more diabetes-related genomic regions

By including multi-ethnic participants, a large-scale genetic study by the University of Exeter has identified more regions of the genome linked to type-2 diabetes-related traits

Two pandemics clash as doctors find that coronavirus spurs diabetes

When Ziyad Al-Aly's research team told him how often diabetes appeared to strike Covid-19 survivors, he thought the data must be wrong, so he asked his five colleagues to crunch the numbers again.

Big Tech uses AI to arrest blindness among India's burgeoning diabetics

Diabetic retinopathy is a leading cause of blindness and vision loss in adults and tech giants such as Intel and Google are building AI-based innovations to address such problems

Covid vaccination voluntary, those already infected can also get the jab

A detailed FAQ released by health ministry has also addressed issues on suitability in co-morbid cases, delivery procedure among other things

AstraZeneca aims to impact 10 mn diabetics by 2023, starts awareness drive

India will have 115 mn diabetics by 2030. Forty-four per cent of patients hospitalised for heart failure have type-2 diabetes

Diabetic eye disease associated with five-fold risk of severe coronavirus

People with diabetes and eye disease have a five-fold increased risk of requiring intubation when hospitalised with Covid-19, suggest the findings of a new study

Ahead of World Diabetes Day, experts call for action to address epidemic

Ahead of World Diabetes Day, a new report has called for action to close the gap in diabetes prevention and care

Sun Pharma arm recalls one lot of diabetes drug Riomet ER oral in US

Sun Pharma has said it is voluntarily recalling one lot of Riomet ER oral suspension in the US market, due to the presence of a probable human carcinogen above the acceptable daily intake limit.